MONMOUTH, N.J., Nov. 2, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc., (OTCBB:VQPH) has accepted an invitation to present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at 10:10 a.m. EDT Wednesday, November 9th at the Palace Hotel in New York. VioQuest is one of over 290 public and private emerging growth biotechnology companies scheduled to present at the conference.
Daniel Greenleaf, president and CEO of VioQuest Pharmaceuticals, will provide a company overview, including a discussion of VioQuest's two in-licensed oncology compounds, one of which, VQD-001, is currently in Phase I clinical trials at The Cleveland Clinic.
The presentation will be webcast live and archived online on VioQuest's website at www.vioquestpharm.com. An audio replay of the presentation will also be available for 90 days after the conference.
About VioQuest Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc.'s strategy is to acquire, develop, and commercialize targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. The company is developing two novel anti-cancer agents, VQD-001 and VQD-002, for the treatment of melanoma, myeloma, lymphoma; and breast, ovarian, pancreatic, colorectal cancers, respectively. VioQuest's life science subsidiary, Chiral Quest, Inc., a pioneer in asymmetric synthesis, offers proprietary chiral catalysts and synthesis expertise for creating important chiral intermediates and products, which improves the safety, efficacy, and manufacturing efficiency of pharmaceutical products. Through Chiral Quest, VioQuest provides products and services to fine chemical manufacturers and 12 of the top 18 pharmaceutical companies worldwide. For more information, please visit www.vioquestpharm.com.
Forward-Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts, and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of VioQuest's research programs and compounds will be successfully commercialized. Risks, uncertainties, and assumptions also include the possibility that the market for the sale of certain products may not develop as expected and that development of these products may not proceed as planned. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2004. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.